Company intelligence / Profile preview
Gennova Biopharmaceuticals Ltd.
- Ownership
- Private
- Employees
- ~530
- Development stage
- Commercial
Overview
Gennova has commercialized at least nine products including five biosimilars, one generic biologic, and a pioneering first-in-world product. It was the first globally to launch a third-generation thrombolytic approved for stroke. Its COVID‑19 mRNA vaccine candidate GEMCOVAC has reached Phase II clinical trials. The company’s products are market leaders in India across several therapeutic areas with significant real-world data supporting their use.
- Therapeutic areas
- OncologyNeurologyCardiovascularNephrologyInfectious Diseases
- Modalities
- BiosimilarsRecombinant proteins/enzymesmRNA vaccinesGeneric biologicsVaccines (including mRNA-based)
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Gennova Biopharmaceuticals Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gennova Biopharmaceuticals Ltd..